Login to Your Account



IPO 'Avalanche' as five more biotechs price offerings

By Jennifer Boggs
Managing Editor

Friday, August 1, 2014
A rush of biotechs entered the public market Thursday morning, led by a $102 million upsized initial public offering (IPO) by Avalanche Biotechnologies Inc., which priced at the high end of its previously raised range, selling 6 million shares at $17 apiece and receiving an enthusiastic welcome on Nasdaq.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription